Dev Prasad
Stock Analyst at Lucid Capital
(4.73)
# 674
Out of 4,630 analysts
16
Total ratings
80%
Success rate
89.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PLYX Polaryx Therapeutics | Initiated Coverage: Buy | $7 | $2.26 | +209.73% | 1 | Jul 27, 2026 | |
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $4.79 | +526.30% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.44 | +145.90% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $49 → $212 | $157.77 | +34.37% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Maintained: Buy | $24 | $1.84 | +1,204.35% | 1 | Nov 10, 2025 | |
| VRCA Verrica Pharmaceuticals | Initiated Coverage: Buy | $19 | $5.08 | +274.02% | 1 | Nov 5, 2025 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Initiated Coverage: Buy | $4.00 | $0.38 | +966.67% | 1 | Oct 14, 2025 | |
| ATYR aTyr Pharma | Downgraded: Hold | $1 | $0.5114 | +95.54% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiated Coverage: Buy | $4 | $27.12 | -85.25% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiated Coverage: Buy | $5 | $3.66 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $5.27 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.59 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.41 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $18.32 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $0.6875 | n/a | 1 | Dec 17, 2024 |
Polaryx Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.26
Upside: +209.73%
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $4.79
Upside: +526.30%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.44
Upside: +145.90%
Palvella Therapeutics
Dec 15, 2025
Maintained: Buy
Price Target: $49 → $212
Current: $157.77
Upside: +34.37%
InflaRx
Nov 10, 2025
Maintained: Buy
Price Target: $24
Current: $1.84
Upside: +1,204.35%
Verrica Pharmaceuticals
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $5.08
Upside: +274.02%
Medicenna Therapeutics Corp.
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.38
Upside: +966.67%
aTyr Pharma
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.5114
Upside: +95.54%
Cue Biopharma
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $27.12
Upside: -85.25%
Opus Genetics
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $3.66
Upside: n/a
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $5.27
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.59
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $1.41
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $18.32
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $0.6875
Upside: n/a